Variant CJD in plasma products
Executive Summary
FDA's Transmissible Spongiform Encephalopathies Advisory Committee will discuss risk assessments for potential exposure to variant Creutzfeldt-Jakob disease (vCJD) agent in plasma products at its Feb. 8 meeting. The committee will also consider possible vCJD risk from investigational coagulation Factor XI manufactured in the 1990s from plasma of donors residing in the U.K. and potential deferral of blood and plasma donors for history of transfusion in France and other European countries. The meeting will be held at the Hilton in Silver Spring, Md. at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com]...